Maximus Health
The performance-positioning telehealth play - enclomiphene, TRT, and semaglutide bundled for buyers who want "optimization" branding.
The performance-positioning telehealth play - TRT, enclomiphene, and semaglutide bundled for buyers who explicitly want "optimization" branding rather than "men's health" branding.
Maximus Health sits in a deliberately different brand corner than Hone or Marek. Same general space - virtual hormone and metabolic protocol delivery - but positioned for a buyer who responds to "performance" and "tribe" language rather than the more medical framing of competitors. Founded 2020, scaled aggressively on Twitter/X and Instagram, and known particularly for its enclomiphene protocol as a fertility-preserving TRT alternative.
The core wedge product is enclomiphene at $89-129/mo. Most TRT protocols suppress natural production and impair fertility - enclomiphene works on the upstream signaling pathway and (in the right candidate) raises endogenous testosterone without the same downstream cost. For 28-40 buyers who want testosterone benefit but plan to have kids, this is a meaningful clinical option, and Maximus runs it more accessibly than most competitors.
Beyond enclomiphene the platform offers standard TRT (similar to Hone's scope), and a semaglutide GLP-1 program for metabolic protocol needs. The semaglutide offering puts Maximus in direct competition with Ro, Hims, and dedicated GLP-1 platforms - generally with sharper pricing than Ro, broader medication scope than dedicated GLP-1 plays, and tighter scope than Marek's full-stack protocol breadth.
Where it wins: enclomiphene category leadership and bundled metabolic + hormone protocols under one membership. Where it loses: the brand voice is divisive (some buyers love the "tribe" framing, some find it off-putting), the protocol scope is narrower than Marek, and the clinical depth on edge cases (high-estradiol management, complex stacks) is shallower than what Defy Medical or Marek run.
Who should buy: 28-45 men prioritizing fertility preservation who want enclomiphene as a TRT alternative, buyers who want hormone and GLP-1 management bundled under one platform, and the audience that explicitly responds to performance/optimization framing. Who shouldn't: anyone who finds the brand voice off-putting (Marek lands cleaner), anyone needing complex multi-drug TRT stacks (Marek deeper), or anyone who only needs basic monitored TRT (Hone cheaper).
Men 28-45 prioritizing fertility preservation (enclomiphene), buyers who want hormone + GLP-1 protocols bundled, and the audience that responds to performance/optimization brand positioning.
You find the brand voice off-putting (Marek lands cleaner clinically), you need complex multi-drug TRT stacks (Marek goes deeper), or you only want basic monitored TRT (Hone is cheaper).
Pros
- Category-leading on enclomiphene accessibility - fertility-preserving alternative to standard TRT
- Bundled hormone + GLP-1 metabolic protocols under one membership
- Sharp pricing on enclomiphene ($89-129/mo) for younger users avoiding HPG-axis suppression
- Strong brand resonance with performance/optimization audience
- Faster onboarding than Marek for users who already know which protocol they want
- Semaglutide pricing competitive vs Ro and dedicated GLP-1 platforms
- Clear protocol-tier separation makes pricing predictable
- Active community presence on X/Twitter signals ongoing brand investment
- Membership covers ongoing labs and clinician access without per-visit fees
Cons
- Brand voice ("tribe", performance language) is polarizing - some buyers prefer Marek's more clinical framing
- Protocol scope narrower than Marek - won't run the same multi-medication TRT stacks
- Edge-case clinical depth (high-E2, complex protocols) shallower than Marek or Defy Medical
- Less established than Hone in mass-market awareness, less clinically deep than Marek
- Membership tier complexity higher than Hone's single-tier model
- Lab panel scope smaller than Marek's 80+ marker comprehensive workup
Specifications
Most often compared with
Where this fits
Maximus Health Performance Protocol Membership cross-shops across several editorial surfaces - the full brand catalog, the buyer-intent tags this item carries, the price band it qualifies for, and any execution playbook that uses it.
Maximus Health Performance Protocol Membership - buyer FAQ
Maximus Health vs Hone vs Marek - which TRT platform?
Three different audiences. Hone ($129-149/mo) is the mass-market entry point for first-time TRT. Maximus ($89-199/mo depending on protocol) is the performance / fertility-preservation angle - enclomiphene is the standout product, plus bundled TRT + semaglutide. Marek ($300-500/mo all-in) is the clinical-premium upgrade for experienced users running multi-medication stacks. Maximus is the right pick if you specifically want enclomiphene or want hormone + GLP-1 under one membership.
Why pick enclomiphene over standard TRT?
Fertility preservation. Standard TRT suppresses the HPG axis and impairs natural testosterone production, which makes restoring fertility difficult after stopping. Enclomiphene works upstream by blocking estrogen feedback in the pituitary, raising endogenous testosterone in the right candidates without HPG suppression. For 28-40 buyers who want testosterone benefit but plan to have kids, enclomiphene is the better protocol. It does not work for everyone - bloodwork response varies more than direct testosterone administration.
Can I do hormone protocols and GLP-1s through one membership?
Yes - that is Maximus's main bundling angle. Hormone tier ($149-199/mo for TRT, $89-129/mo for enclomiphene) and semaglutide GLP-1 tier ($199-299/mo) can run concurrently under one platform with one clinical team. This is rare - most telehealth platforms specialize in one or the other. For buyers managing both protocols, the bundling simplifies the clinical workflow significantly.